CollPlant Biotechnologies... (CLGN)
CollPlant Biotechnologies Ltd. Statistics
Share Statistics
CollPlant Biotechnologies Ltd. has 11.45M shares outstanding. The number of shares has increased by 0.02% in one year.
Shares Outstanding | 11.45M |
Shares Change (YoY) | 0.02% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 0.03% |
Shares Floating | 7.68M |
Failed to Deliver (FTD) Shares | 84 |
FTD / Avg. Volume | 0.98% |
Short Selling Information
The latest short interest is 12.07K, so 0.11% of the outstanding shares have been sold short.
Short Interest | 12.07K |
Short % of Shares Out | 0.11% |
Short % of Float | 0.15% |
Short Ratio (days to cover) | 0.7 |
Valuation Ratios
The PE ratio is -10.37 and the forward PE ratio is -9.62. CollPlant Biotechnologies Ltd.'s PEG ratio is 0.18.
PE Ratio | -10.37 |
Forward PE | -9.62 |
PS Ratio | 6.64 |
Forward PS | 2.1 |
PB Ratio | 2.57 |
P/FCF Ratio | -19.58 |
PEG Ratio | 0.18 |
Enterprise Valuation
CollPlant Biotechnologies Ltd. has an Enterprise Value (EV) of 49.02M.
EV / Earnings | -6.98 |
EV / Sales | 4.47 |
EV / EBITDA | -7.65 |
EV / EBIT | -6.53 |
EV / FCF | -13.19 |
Financial Position
The company has a current ratio of 8.62, with a Debt / Equity ratio of 0.11.
Current Ratio | 8.62 |
Quick Ratio | 8.4 |
Debt / Equity | 0.11 |
Total Debt / Capitalization | 10.03 |
Cash Flow / Debt | -0.87 |
Interest Coverage | -751.2 |
Financial Efficiency
Return on equity (ROE) is -0.25% and return on capital (ROIC) is -23.85%.
Return on Equity (ROE) | -0.25% |
Return on Assets (ROA) | -0.21% |
Return on Capital (ROIC) | -23.85% |
Revenue Per Employee | $146,120 |
Profits Per Employee | $-93,586.67 |
Employee Count | 75 |
Asset Turnover | 0.32 |
Inventory Turnover | 2.79 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -48.18% in the last 52 weeks. The beta is 0.7, so CollPlant Biotechnologies Ltd.'s price volatility has been higher than the market average.
Beta | 0.7 |
52-Week Price Change | -48.18% |
50-Day Moving Average | 3.49 |
200-Day Moving Average | 4.27 |
Relative Strength Index (RSI) | 28.77 |
Average Volume (20 Days) | 8.59K |
Income Statement
In the last 12 months, CollPlant Biotechnologies Ltd. had revenue of 10.96M and earned -7.02M in profits. Earnings per share was -0.62.
Revenue | 10.96M |
Gross Profit | 8.97M |
Operating Income | -7.51M |
Net Income | -7.02M |
EBITDA | -6.41M |
EBIT | -7.51M |
Earnings Per Share (EPS) | -0.62 |
Balance Sheet
The company has 26.67M in cash and 3.16M in debt, giving a net cash position of 23.52M.
Cash & Cash Equivalents | 26.67M |
Total Debt | 3.16M |
Net Cash | 23.52M |
Retained Earnings | -96.74M |
Total Assets | 22.44M |
Working Capital | 13.43M |
Cash Flow
In the last 12 months, operating cash flow was -2.76M and capital expenditures -954K, giving a free cash flow of -3.72M.
Operating Cash Flow | -2.76M |
Capital Expenditures | -954K |
Free Cash Flow | -3.72M |
FCF Per Share | -0.33 |
Margins
Gross margin is 81.83%, with operating and profit margins of -68.55% and -64.05%.
Gross Margin | 81.83% |
Operating Margin | -68.55% |
Pretax Margin | -64.05% |
Profit Margin | -64.05% |
EBITDA Margin | -58.49% |
EBIT Margin | -68.55% |
FCF Margin | -33.92% |
Dividends & Yields
CLGN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -22.88% |
FCF Yield | -12% |
Analyst Forecast
The average price target for CLGN is $14, which is 416.6% higher than the current price. The consensus rating is "Buy".
Price Target | $14 |
Price Target Difference | 416.6% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Stock Splits
The last stock split was on Dec 1, 2016. It was a backward split with a ratio of 2:3.
Last Split Date | Dec 1, 2016 |
Split Type | backward |
Split Ratio | 2:3 |
Scores
Altman Z-Score | -5.3 |
Piotroski F-Score | 1 |